After undergraduate and graduate training at MIT and Harvard Medical School, Internal Medicine training at MGH, and postdoctoral and Cardiology training at UCSF, Dr. Coughlin joined the UCSF faculty in 1986. He served as Director of UCSF’s Cardiovascular Research Institute from 1997-2017. Coughlin’s laboratory at UCSF sought to identify regulatory mechanisms governing cardiovascular biology and disease. The laboratory’s discovery of a thrombin receptor, now known as protease-activated receptor-1 (PAR1), revealed the molecular mechanism by which thrombin, a protease, can function as a signaling molecule to regulate the behavior of platelets and other cells like hormones do. The laboratory’s characterization of PAR1 and other members of the PAR family led to a greater understanding of how cells sense tissue injury and trigger responses that stop bleeding and promote inflammation and repair. Dr. Coughlin joined Novartis in 2017 to help lead the development of medicines to prevent, treat or reverse important cardiovascular diseases.

Research Interests

Currently directing discovery research in cardiovascular and metabolism at Novartis. Areas of focus are atherosclerosis, heart failure, obesity-driven diseases, and atrial fibrillation.

Membership Type


Election Year


Primary Section

Section 42: Medical Physiology and Metabolism

Secondary Section

Section 41: Medical Genetics, Hematology, and Oncology